Biogen Idec Inc.

James C. Mullen is President and Chief Executive Officer of Biogen Idec and has served in these positions since the merger in November 2003. Mr. Mullen joined Biogen Inc. in 1989. He was named Chief Executive Officer in 2000 and Chairman in 2002. Prior to being named CEO and Chairman, he also held the positions of President and Chief Operating Officer (1999-2000); Vice President, International (1996-1999); Vice President, Operations (1992-1996); and Director, Facilities and Engineering (1989-1992). Mr. Mullen is a member of the Board of Directors of PerkinElmer Inc. and the Biomedical Science Careers Program Inc. He holds a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute and an M.B.A. from Villanova University.

Michael F. MacLean is our Senior Vice President, Chief Accounting Officer and Controller and has served in that position since December 2006. Mr. MacLean joined Biogen Idec in October 2006 as Senior Vice President. Prior to that, Mr. MacLean was a managing director of Huron Consulting, where he provided support regarding financial reporting to management and boards of directors of Fortune 500 companies. From June 2002 to October 2005, Mr. MacLean was a partner at KPMG, and from September 1999 to May 2002, he was a partner of Arthur Andersen LLP.

Paul J. Clancy is our Executive Vice President and Chief Financial Officer and has served in these positions since August 2007. Mr. Clancy has also served as Senior Vice President of Finance and Vice President of Business Planning at Biogen Idec. Prior to the merger, Mr. Clancy had served as Vice President of Portfolio Management at Biogen Inc. since 2003. He joined the company in 2001 as Vice President, US Marketing. Before joining Biogen, Mr. Clancy spent 13 years at PepsiCo, serving in a range of financial and general management positions including most recently Vice President and General Manager of their Great West Business Unit.

Robert A. Hamm is our Chief Operating Officer and has served in that position since March 2009. Prior to that, Mr. Hamm had served as our Executive Vice President, Pharmaceutical Operations & Technology since October 2007. He served as Senior Vice President, Neurology Strategic Business Unit beginning from 2004 to 2007. Since joining the company in 1994, he has served in a variety of positions of increasing responsibility, including Senior Vice President, Europe, Africa, Canada and Middle East; Vice President, Sales and Marketing; Vice President, Manufacturing & Engineering; and Director, Northern Europe and Distributors Markets. From 1987 to 1994, he held a variety of management positions at Syntex Laboratories Corp. He is a member of the board of directors Inhibitex, Inc. and Progenitor Cell Therapy, LLC.

Craig Eric Schneier, Ph.D. is our Executive Vice President, Human Resources, Public Affairs & Corporate Communications and has served in that position since the merger in November 2003. Dr. Schneier was previously Executive Vice President, Human Resources of Biogen, Inc., a position he held since January 2003. He joined Biogen, Inc. in 2001 as Senior Vice President, Strategic Organization Design and Effectiveness, after having served as an external consultant to the company for eight years. Prior to joining Biogen, Inc., Dr. Schneier was president of his own management consulting firm in Princeton, NJ, where he provided consulting services to over 70 of the Fortune 100 companies, as well as several of the largest European and Asian firms. Dr. Schneier held a tenured professorship at the University of Maryland?s Smith School of Business and has held teaching positions at the business schools of the University of Michigan, Columbia University, and at the Tuck School of Business, Dartmouth College.

Array

John M. Dunn is our Executive Vice President, New Ventures and has served in that position since the merger in November 2003. Mr. Dunn was our Senior Vice President, Legal and Compliance, and General Counsel from January 2002 to November 2003. Prior to that, he was a partner at the law firm of Pillsbury Winthrop LLP, specializing in corporate and business representation of public and private companies.

John M. Dunn is our Executive Vice President, New Ventures and has served in that position since the merger in November 2003. Mr. Dunn was our Senior Vice President, Legal and Compliance, and General Counsel from January 2002 to November 2003. Prior to that, he was a partner at the law firm of Pillsbury Winthrop LLP, specializing in corporate and business representation of public and private companies.

Mark C. Wiggins is our Executive Vice President, Corporate and Business Development and has served in that capacity since July 2004. Prior to that, Mr. Wiggins served as our Senior Vice President, Business Development from November 2003 to July 2004, Vice President of Marketing and Business Development from November 2000 to November 2003, and Vice President of Business Development from May 1998 to November 2000. From 1996 to 1998, he was Vice President of Business Development and Marketing for Hybridon. From 1986 to 1996 he held various positions of increasing responsibility at Schering-Plough Corporation, including Director of Business Development.

Michael Gilman, Ph.D. is President and CEO of Stromedix, Inc. and most recently served as Executive Vice President of Research at Biogen Idec, Inc. During his six-year tenure at Biogen Idec, from 1999 to 2005, Dr. Gilman managed discovery research including inflammatory and autoimmune diseases, and cancer. From 1994 to 1999, Dr. Gilman served as Executive Vice President and Chief Scientific Officer of Ariad Pharmaceuticals Inc. where he was responsible for drug discovery activities to develop novel gene- and cell-regulation technologies. Earlier in his career, Dr. Gilman was a principal investigator at Cold Spring Harbor Laboratory where he ran an active research programs in growth control and cancer, signal transduction and gene transcription and held adjunct academic appointments at SUNY Stony Brook. He earned a Ph.D. in Biochemistry from the University of California, Berkeley, and holds an S.B. in Life Sciences from the Massachusetts Institute of Technology.

Michael Lytton is our Executive Vice President, Corporate and Business Development, and has served in that position since February 2009. From 2001 to 2009, he was a General Partner at Oxford Bioscience Partners, a venture capital firm. From 1993 to 2000, he was Partner, Chairman of the Technology Group and a member of the Executive Committee of the law firm Edwards, Angell, Palmer & Dodge LLP. From 1984 to 1993, Mr. Lytton was a Junior Partner and Co-Chairman of the Biotechnology Practice of the law firm Wilmer Hale.

Susan H. Alexander is our Executive Vice President, General Counsel and Corporate Secretary and has served in these positions since January 2006. Prior to that, Ms. Alexander had served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corp. since September 2003. From June 2001 to September 2003, Ms. Alexander served as General Counsel of IONA Technologies. From January 1995 to May 2001, Ms. Alexander served as Counsel at Cabot Corp. Prior to that, Ms. Alexander was a partner of the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne.

Michael D. Kowolenko, Ph.D. is our Senior Vice President, Pharmaceutical Operations and Technology, and has served in that position since July 2004. Prior to that, he served as our Senior Vice President, Global Quality, from November 2003 to July 2004 and held a similar position with Biogen, Inc. from April 2002 until November 2003. Prior to joining Biogen, Inc., Dr. Kowolenko held several positions within Research, Development, and Operations at Bayer Corporation, including Vice President of Quality Assurance from January 2001 to April 2002.

Jane Amara is Associate Director of Business Development at Biogen Idec. Since joining Biogen five years ago, she has been working to find, evaluate, negotiate and execute business deals for therapeutics and technologies. Jane?s background is on the technical side of biotech. Jane earned a Ph.D. in Pharmacology at Yale University followed by postdoctoral research at the Whitehead Institute, then worked as a research scientist at several companies including Genzyme and ARIAD Pharmaceuticals. While at ARIAD she transitioned to the business side of the company with a role in technology transfer and program management as Director of Technology Management.

Jose Juves is the Director of Public Affairs for Biogen Idec, where he oversees corporate and financial media relations for one of the world's top biotechnology companies. His responsibilities include general media relations, executive communications, crisis management, community relations, supporting product public relations and managing the Community Lab a program that invites local middle and high school students to Biogen Idec to work in a lab and learn about biotechnology. Prior to joining Biogen Idec, Jose served in the state government in many capacities, most recently as the spokesperson for Massport. He serves on the Advisory Board of the East Boston YMCA.

Christine has been a resident of Malta for 12 years. She works for Biogen Idec in pharmeceutical sales. Christine recently was President for the Malta Avenue Intermediate School PTA and still serves on committees. She also participates on the Shared Decision Making Team at Malta Avenue. Christine and her family are active in the Arthritis Foundation. Christine and her husband, Todd, have three children in Ballston Spa Schools. Christine has been a member of the board since November 2007.

Heather Frahm co-founded Catalyst online in 1998 upon recognizing the emerging need for experts in the online marketing industry for healthcare companies. Her success is evident in Catalyst online's list of clients including: Pfizer, Novartis, Biogen Idec, Diomed, Noven, Genzyme, Aurora and Drug Information Association . Prior to Catalyst online, Heather served as a Assistant Vice President in the Financial Institutions Group at BankBoston and a contributing member of BankBoston's Internet Marketing Team. Her extensive experience in the financial services industry also includes positions at State Street Bank and Trust, Donaldson Lufkin, & Jenrette, and Goldman Financial Group. She received her BA in Economics from Hartwick College and her MBA at the Boston College Carroll School of Management. Currently, Heather is an active board member for the Healthcare Businesswomen's Association.

Lynn Schenk is an attorney in private practice. She served as Chief of Staff to the Governor of California from January 1999 to November 2003. Ms. Schenk was previously an attorney in private practice from 1996 to 1998 and from 1983 to 1993. Ms. Schenk served as the U.S. Representative for the 49th District of the State of California from 1993 to 1995 and served as the California Secretary of Business, Transportation and Housing from 1980 to 1983. She received her B.A. in Political Science from the University of California at Los Angeles, earned her J.D. from the University of San Diego and attended the London School of Economics. Ms. Schenk began serving as a Director of IDEC Pharmaceuticals in 1995. She is also a member of the Board of Trustees of The Scripps Research Institute.

Jo-Dee has over 20 years of experience in the design and implementation of integrated compensation strategies including the assessment and development of executive total compensation plans, sales and management incentive plans, equity-based pay programs and market/competency based salary systems. Jo-Dee is highly experienced in developing competency models used in performance management, selection, workforce planning and compensation programs. She also has extensive experience in the development and communication of employee benefit programs and implementation of HRM Systems. Jo-Dee is a specialist in the biopharmaceutical industry having worked with companies across the full range of sizes and product stages such as Genzyme, Biogen Idec, Antigenics, Hypnion, and Alnylam Pharmaceuticals. She also has in-depth experience in the financial services, retail and high technology industries, and in working with companies to implement acquisitions and mergers. Jo-Dee has been actively involved with steering committees for key national and regional surveys. She has made numerous professional presentations, particularly on the design of incentives and broad-based stock plans. Jo-Dee was a recipient of a Lifetime Achievement Award from the WorldatWork in 1997. She has degrees from Mount Holyoke College and Harvard University.

Lawrence C. Fritz joined Anadys as President and Chief Executive Officer and a member of the Board of Directors on November 20, 2006. Previously, he founded and developed several successful biotechnology companies. He founded Conforma Therapeutics and served as its President and CEO from inception in 1999 through its acquisition by Biogen Idec in 2006. Conforma pioneered a new approach to cancer therapy, developing drugs that induce tumor cells to degrade their deregulated signaling proteins. Dr. Fritz is also a founder and Director of Cabrellis Pharmaceuticals, a specialty pharma cancer company spun-out from Conforma in conjunction with Biogen Idec's acquisition. Prior to Conforma, Dr. Fritz co-founded both Athena Neurosciences, now wholly-owned by Elan Corporation, and Idun Pharmaceuticals, subsequently acquired by Pfizer. As Vice President of Research at Athena, his work led to the clinical development of products for multiple sclerosis, Alzheimer's disease, and neuromuscular disorders. While Executive Vice President, Research at Idun, he led R&D teams that pioneered pharmaceutical applications in the field of programmed cell death, or apoptosis. These efforts led to new approaches to the treatment of hepatitis C, inflammation, and cancer. Dr. Fritz holds an A.B. Degree in Biochemical Sciences from Harvard, a M.Sc. Degree in Physiology from University College London, and a Ph.D. in Biophysics from The Rockefeller University.

Lisa Fuller is 33 years old and lives in Cambridge, Massachusetts. She is a registered nurse and after many years of providing bedside care for Oncology patients, she now manages global clinical trials for Biogen Idec. Lisa is also a part-time graduate student at Boston University and is working on a Masters of Business Administration in Health Sector Management. Lisa had always wanted to volunteer in Africa and found her way to HardtHaven through Cosmic Volunteers. Her first trip to Kpando was in December of 2007 and she fell immediately in love with the country, the people and especially the children. Once back in the US, she became increasingly involved with the organizational aspect of HardtHaven and made her second trip to Ghana in March of 2008. She has recently joined the Board of Directors for HardtHaven and is currently planning her next trip to Kpando.

Mark de Souza is Senior Director of Corporate Development at Dyax Corp. Since 2001, his primary focus is partnering Dyax?s phage display technology for the discovery and development of biopharmaceuticals from Dyax?s antibody, peptide, and protein libraries. He is responsible for initiating new collaborations, in-licensing new technology, marketing Dyax?s scientific and business achievements, and managing existing alliances. Dyax currently has over 75 licensees and collaborators, including Amgen, AstraZeneca, Baxter, Biogen Idec, Genzyme, ImClone Systems, MedImmune, and Tanox.

Mr. Johnson has a proven track record with more than 20 years of healthcare experience in marketing and general management with professional service companies providing consultation to leading corporations including Abbott, Amgen, Baxter, Beckman Coulter, Biogen Idec, Guidant, Johnson & Johnson, 3M Healthcare and emerging companies. Mr. Johnson has supported the launch of more than 200 global brands. He has a BBA in marketing from the University of Texas and an MBA in finance from Michigan State University.

Dr. Hsu is currently a Principal Scientist in the Drug Development Group in Research Department at BiogenIdec, Inc. Cambridge, Massachusetts. Dr. Hsu obtained his Ph.D. in Biochemistry at Michigan State University and received his post-doctoral training in the Department of Biochemistry and Molecular Biology at Harvard University. He joined the Protein Engineering Department at the legacy Biogen, Inc. as a staff scientist in 1990. Over the past 15 years, Dr. Hsu has established a state of art protein engineering laboratory, specifically in the areas of protein foldings as well as protein-protein interactions. In addition, Dr. Hsu has been working on the research and development of a number of protein therapeutics each targets to regulate a critical pathway in human immune system. Most recently, his research focuses on the identification and development of a novel protein drug aiming to effectively slow down the disease progression in a number of autoimmune disorders by controlling life and death of B lymphocytes at different developmental stages. Dr. Hsu has been a Board Director of since year 2000 and was elected as the Chairman since August, 2005.

In late January 2009, Dr. Denner was interviewed by Messrs. LeBuhn, Micati and Salisbury, and Professor Mulligan was interviewed by Drs. Ando and Geltosky and, at their invitation, Dr. Ivan Horak, the Company s Executive Vice President, Research and Development and Chief Scientific Officer. At a meeting of the Governance and Nominating Committee held on January 28, 2009, the Committee determined to recommend to the Board the nominations of Dr. Denner and Professor Mulligan for election as Class I Directors at the Annual Meeting. At a meeting of the Board held later that day, the Board determined to accept the recommendation of the Governance and Nominating Committee and nominated Dr. Denner and Professor Mulligan for election as Class I Directors at the Annual Meeting. At the request of the Icahn Group, the Board committed to the Icahn Group that if, for any reason, the Board subsequently determined not to nominate both Dr. Denner and Professor Mulligan, or to nominate any persons in addition to Dr. Denner and Professor Mulligan, for election as Class I Directors at the Annual Meeting, the Company would give the Icahn Group prompt written notice thereof and the Company would take all necessary action to permit the Icahn Group to nominate persons named in a notice of nomination for election to the Board which the Icahn Group would deliver to the Company on or before the close of business on the tenth day following the date on which the Icahn Group received such written notice from the Company.

Brian S. Posner, a private investor, served as Chief Executive Officer and co-Chief Investment Officer of ClearBridge Advisors LLC from 2005 until March 2008. ClearBridge, a wholly owned subsidiary of Legg Mason Inc., is an asset management company based in New York with approximately $90 billion in assets. Prior to joining ClearBridge, Mr. Posner co-founded Hygrove Partners LLC, a hedge fund, in 2000 and served as the Managing Partner for five years. He served as a Portfolio Manager and an Analyst at Fidelity Investments from 1987 to 1996 and, from 1997 to 1999, at Warburg Pincus Asset Management/Credit Suisse Asset Management. Mr. Posner holds an undergraduate degree in history from Northwestern University and an M.B.A. in finance from the University of Chicago Graduate School of Business. Mr. Posner began serving as a director of Biogen Idec in 2008.

Lawrence Best has been a Board Member since 2003. Mr. Best recently retired as Senior Vice President and Chief Financial Officer for Boston Scientific. Previously, he was a partner in the accounting firm of Ernst & Young. He has served as a fellow at the Securities and Exchange Commission and as a White House-appointed Presidential Exchange Executive. (Audit Committee Member)

Marijn E. Dekkers is President and Chief Executive Officer of Thermo Fisher Scientific Inc. and has served in that position since the merger of Thermo Electron Corp. and Fisher Scientific International in November 2006. Prior to that merger, Mr. Dekkers was President and Chief Executive Officer of Thermo Electron Corp., a position he held since November 2002. He served as Thermo's President and Chief Operating Officer from July 2000 to November 2002. Prior to joining Thermo Electron Corp., Mr. Dekkers held various positions of increasing responsibility at Honeywell International Inc. (formerly AlliedSignal Inc.) and General Electric Co. Mr. Dekkers is also a director of Thermo Fisher Scientific.

Nancy L. Leaming retired in 2005 as President and CEO of Tufts Health Plan. For 20 years, Ms. Leaming served in several executive positions at Tufts Health Plan, including President and CEO (2003 - 2005), President and Chief Operating Officer (1997-2003) and Chief Operating Officer (1986-1997). Ms. Leaming successfully led the managed care company to become a nationally recognized leader in its field, creating a strategic vision and strong corporate culture defined by product innovation, service excellence, quality and patient safety. She has served in various capacities on both commercial and non-profit boards. Ms. Leaming is currently a member of the boards of directors at Hologic Inc., where she chairs the Audit Committee, Edgewater Technology Inc., the Massachusetts Taxpayers Foundation and the American Red Cross of Massachusetts.

Dr. Mulligan is the Mallinckrodt Professor of Genetics at Harvard Medical School and Director of the Harvard Gene Therapy Initiative. Dr. Mulligan received his B.S. from the Massachusetts Institute of Technology and his Ph.D. from the Department of Biochemistry at Stanford University School of Medicine. After receiving postdoctoral training at the Center for Cancer Research at MIT, Dr. Mulligan joined the MIT faculty and subsequently was appointed Professor of Molecular Biology and Member of the Whitehead Institute for Biomedical Research before moving to Children's Hospital and Harvard in 1996. Dr. Mulligan has been associated with a number of biotechnology companies, including Somatix Therapy Corporation (as founder, director, Scientific Advisory Board member and Chief Scientific Officer), Cell Genesys, Inc. (as Scientific Advisory Board member) and ImClone Systems Incorporated (as director and Scientific Advisory Board member). Dr. Mulligan is currently a director of Enzon Pharmaceuticals, Inc.

Robert W. Pangia has worked in investment banking for 20 years and is currently a partner in Ivy Capital Partners LLC and general partner of Ivy Healthcare Capital L.P., a private equity fund specializing in healthcare investments. From 1996 to February 2003, Mr. Pangia was self-employed as an investment banker. From 1987 to 1996, Mr. Pangia held various senior management positions at PaineWebber Inc. including: member of the board of directors, Chairman of the board of directors of PaineWebber Properties Inc., member of PaineWebber's executive and operating committees, Chairman of the equity commitment committee, member of the debt commitment committee and Executive Vice President and Director of Investment Banking for PaineWebber Inc. of New York. Prior to his positions at PaineWebber, Mr. Pangia held other senior positions, including Managing Director of Investment Banking for Drexel Burnham Lambert of New York and Vice President of Investment Banking for Kidder, Peabody & Co. of New York. He received his A.B. from Brown University and his M.B.A. from Columbia University. Mr. Pangia began serving as a Director of IDEC Pharmaceuticals in September 1997. He is also a Director of McAfee Inc.

Stelios Papadopoulos, Ph.D. is a co-founder of Anadys and has served as a member of our board of directors since May 2000. His career in biotech spans more than two decades. In August 2006 he resigned as Vice Chairman of Cowen & Co., LLC where he had been an investment banker focused on the biotechnology and pharmaceutical sectors since 2000. Dr. Papadopoulos was an investment banker at PaineWebber Incorporated from 1987 to 2000, most recently serving as Chairman of Paine Webber Development Corp., a PaineWebber subsidiary focusing on biotechnology. Prior to joining PaineWebber in 1987 he was a Vice President in the Equity Research Department of Drexel Burnham Lambert covering the biotechnology industry and a biotechnology analyst at Donaldson, Lufkin & Jenrette. Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with New York University Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds a Ph.D. in biophysics and an M.B.A. in finance, both from New York University. He is co-founder and Chairman of the Board of Exelixis, Inc., co-founder and member of the Board of Cellzome Inc., as well as a member of the Board of Directors of Biogen Idec and BG Medicine, Inc. In the not-for-profit sector, he is co-founder and Chairman of Fondation Santé and a member of the Board of Visitors of Duke University Medical Center.